PAHC

Phibro Animal Health (PAHC), an animal health products and nutritional supplements maker, is highlighted as a strong candidate for beating upcoming earnings estimates. The company has consistently exceeded earnings expectations over the past two quarters with an average surprise of 11.81%. With a positive Earnings ESP of +2.10% combined with a Zacks Rank #1 (Strong Buy) rating, analysts suggest the stock has a high probability of delivering another earnings beat.

A comparison of two medical products sector stocks reveals Phibro Animal Health (PAHC) as the superior value opportunity. PAHC holds a Zacks Rank #1 (Strong Buy) with a forward P/E of 11.12 and Value grade of B, while Stryker (SYK) has a Zacks Rank #4 (Sell) with a forward P/E of 20.39 and Value grade of D. PAHC's stronger earnings outlook and more attractive valuation metrics make it the better choice for value investors.

Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results.

ResMed is set to report Q1 fiscal 2027 results on October 29, with revenues projected at $1.39 billion (up 4%) and EPS expected to rise 4.7% to $2.67. The Sleep and Breathing Health segment is anticipated to grow 6.4% driven by device demand and new product launches, while Residential Care Software revenues are expected to decline 12.7% following the September 2026 sale of MatrixCare to Frazier Healthcare Partners. The company has a Zacks Rank #3 with a negative Earnings ESP of -0.60%.

Quest Diagnostics (DGX) reported Q3 2026 adjusted earnings of $3.00 per share (up 15.4% YoY) and revenues of $3.10 billion (up 10% YoY), both beating consensus estimates. The company raised full-year 2026 revenue guidance to $12.065-$12.105 billion and adjusted EPS outlook to $11.25-$11.35.

Despite strong results, DGX shares fell 1.6% in pre-market trading. Operating margins improved 40 basis points to 16.7%, driven by strong testing demand and organic requisition volume growth of 14.4%.

Elevance Health reported Q3 2026 adjusted EPS of $6.99, significantly beating estimates by 50%, with revenue reaching $50.4B. The Carelon segment drove growth with 5.4% revenue increase and 17.2% operating gain growth. The company raised its 2026 adjusted EPS guidance to at least $29.00 and increased its earnings baseline to at least $26.75.

Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures.

STERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth.

Medtronic is expanding its presence in high-growth markets including cardiac ablation (up 88%), robotics, and structural heart, while advancing the MiniMed separation. The company is building its hypertension business through the Symplicity Spyral renal denervation franchise with improved reimbursement and clinical evidence. However, Medtronic faces headwinds from tariffs, inflation, currency fluctuations, and unfavorable product mix that could pressure margins.

Prestige Consumer Healthcare (PBH) is building its consumer health brand portfolio through strategic acquisitions of Breathe Right and LaCorium, expected to contribute $190 million in fiscal 2027 revenues. The company benefits from strong e-commerce growth at double-digit rates and brand-building initiatives across established franchises.

However, intense competition, pricing pressure, and foreign exchange fluctuations pose ongoing challenges. PBH holds a Zacks Rank #3 (Hold) rating with an earnings yield of 9.4%, outpacing the industry average.

Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026.

Encompass Health Corporation (EHC) opened its first wholly owned hospital in Maine with 50 inpatient rehabilitation beds. Q2 2026 discharges rose 5.6% year-over-year, driven by new capacity and 2.8% same-store growth. EHC opened three hospitals in the first half of 2026 and plans to open eight new hospitals throughout the year, reflecting its strategy to expand capacity in favorable markets.

Thermo Fisher Scientific (TMO) is strengthening growth through innovation, AI investments, and strategic acquisitions expected to contribute $1.6 billion in revenues and 32 cents to adjusted EPS in 2026. The company expects organic revenue growth at 3%-4% for 2026 supported by broad-based end-market improvements. However, risks from macroeconomic uncertainty, inflation, geopolitical disruption, and unfavorable currency movements could weigh on results and margins.

Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028.

Integra LifeSciences (IART) reported 1.6% organic growth in Specialty Surgery revenues driven by neurosurgery strength and improved supply reliability. Adjusted EPS rose 24.4% with margin expansion, and the company is ramping up Braintree production for a SurgiMend relaunch. However, elevated leverage at 4.1X and foreign exchange headwinds pressured full-year revenue guidance and financial flexibility.

Chewy's Vet Care portfolio achieved triple-digit revenue growth in Q2, demonstrating strong customer satisfaction, veterinarian retention, and compelling clinic economics. The company expects its Health segment, including Modern Animal, to deepen customer engagement and expand wallet share as it scales. However, Chewy carries a Zacks Rank #4 (Sell) rating and has underperformed its industry by 44.7% over the past six months.

Labcorp Holdings is expanding its specialty testing business in oncology, women's health, autoimmune disease, and neurology through strategic acquisitions and partnerships. The company is leveraging AI and automation to improve margins, with operating margins expanding 70 basis points year-over-year. However, macroeconomic uncertainty, cost inflation, and changing reimbursement policies pose risks to testing volumes and profitability.